Genmab — Juni 2019
-
@ 07:21 we are getting some early data on the SC DARA + CyBorD AL amyloidosis.trial. early, but ORR 96% , VGPR 82%; 36% CR
https://learningcenter.ehaweb.org/eha/2019/24th/267458/raymond.l.comenzo.subcutaneous.daratumumab.2B.cyclophosphamide.bortezomib.and.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Ddaratumumab%2Bamyloidosis -
Thanks EL. Funny that the date on the paper is june 15 2019
-
Pyha, vinden blæser ikke vores vej
-
Var det ikke 12000 pts i denne gruppe. Ninlaro fra Takeda stoppede netop en fase 3 i denne indikation i går https://finance.yahoo.com/news/takeda-provides-tourmaline-al1-phase-203000255.html
-
ok. saw these tweets earlier this week from a big kidney conference in the Uk, assuming they are using the same data https://twitter.com/jeremyblevy/status/1135951536822128640 https://twitter.com/jeremyblevy/status/1135953801477873665
-
i am just reading this article , which seems to think Feb 2020 https://www.evaluate.com/vantage/articles/analysis/takeda-casts-doubt-remaining-approach-amyloidosis
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind